ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prednisolone"

  • Abstract Number: 397 • 2013 ACR/ARHP Annual Meeting

    Does Elevated Disease Activity Or Medication Use Influence The Bone Density Of The Prepubertal Offspring In Pregnant Women With Rheumatoid Arthritis?

    Florentien D.O. de Steenwinkel1, Anita C.S. Hokken-Koelega2, Johanna Hazes3 and Radboud J.E.M. Dolhain1, 1Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 2Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands, 3Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands

    Background/Purpose: Elevated rheumatoid arthritis disease activity and prednisone use during pregnancy  are both associated with a lower bone mineral density (BMD) of the patients, but…
  • Abstract Number: 398 • 2013 ACR/ARHP Annual Meeting

    Does Elevated Disease Activity Or Medication Use Influence The Body Composition Of The Prepubertal Offspring In Pregnant Women With Rheumatoid Arthritis?

    Florentien D.O. de Steenwinkel1, Radboud J.E.M. Dolhain1, Johanna M.W. Hazes2 and Anita C.S. Hokken-Koelega3, 1Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 2Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 3Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands

    Background/Purpose: Elevated rheumatoid arthritis (RA) disease activity during pregnancy is associated with lower birth weight and rapid post-natal growth. Lower birth weight and rapid post-natal…
  • Abstract Number: 2681 • 2013 ACR/ARHP Annual Meeting

    Reduced Fertility In Women With Rheumatoid Arthritis: Influence Of Disease Activity and Medication Use

    Jenny Brouwer1,2, Johanna MW Hazes1, Joop SE Laven2 and Radboud JEM Dolhain1, 1Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 2Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

    Background/Purpose: Many female rheumatoid arthritis (RA) patients who try to conceive have a time to pregnancy (TTP) longer than 12 months.  During this period RA…
  • Abstract Number: 2336 • 2013 ACR/ARHP Annual Meeting

    Phase 2 Evaluation Of PF-04171327, a Dissociated Agonist Of The Glucocorticoid Receptor, For The Treatment Of Rheumatoid Arthritis In Patients With An Inadequate Response To Methotrexate

    Thomas Stock1, Dona Fleishaker2, Xin Wang2, Arnab Mukherjee2 and Charles Mebus2, 1Pfizer Inc., Collegeville, PA, 2Pfizer Inc., Groton, CT

    Background/Purpose: PF-04171327, a pro drug of PF-00251802, is under investigation as a potential dissociated agonist of the glucocorticoid receptor (DAGR). PF-00251802 is a selective high-affinity…
  • Abstract Number: 2255 • 2013 ACR/ARHP Annual Meeting

    Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year

    Frank Buttgereit1, Jeffery Kent2, Robert Holt2, Amy Grahn3, Patricia Rice4, Rieke Alten5 and Yusuf Yazici6, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, 3Clinical Development, Horizon Pharma, Inc, Deerfield, IL, 4Statistics, CliniRx Research, Naperville, IL, 5Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, 6New York University, New York, NY

    Background/Purpose: RA patients typically present with pain and morning stiffness (MS) in addition to joint swelling and tenderness.  Nocturnal inflammatory cytokines are assumed to be…
  • Abstract Number: 2265 • 2013 ACR/ARHP Annual Meeting

    Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)

    Rieke Alten1, Robert Holt2, Amy Grahn3, Patricia Rice4, Jeffery Kent2, Frank Buttgereit5 and Allan Gibofsky6, 1Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, 2Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, 3Clinical Development, Horizon Pharma, Inc, Deerfield, IL, 4Statistics, CliniRx Research, Naperville, IL, 5Charité - Universitätsmedizin Berlin, Berlin, Germany, 6Medicine and Public Health, Hospital for Special Surgery, New York, NY

    Background/Purpose:    A surge in nocturnal inflammatory cytokines causing morning stiffness (MS) is recognized as a therapeutic target in RA. MS has been underappreciated in…
  • Abstract Number: 367 • 2012 ACR/ARHP Annual Meeting

    Improved Fatigue-Related Quality of Life in CAPRA-2, a 12 Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis

    Rieke Alten1, Amy Grahn2, Patricia Rice3 and Frank Buttgereit4, 1Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, 2Clinical Development, Horizon Pharma, Inc, Deerfield, IL, 3Statistics, CliniRx Research, Naperville, IL, 4Charité - Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Quality of life in rheumatoid arthritis (RA) patients can be improved by reducing the common symptom of fatigue caused by disease related factors such…
  • Abstract Number: 353 • 2012 ACR/ARHP Annual Meeting

    The Effect of Combination Therapy and Prednisolone On Haemostatic Markers in Rheumatoid Arthritis

    Inge A.M. van den Oever1, Danka J.F. Stuijver2, Debby den Uyl3, Bregje van Zaane4, Marieke M. ter Wee5, Willem F. Lems5, Dirkjan van Schaardenburg1, Joost C.M. Meijers4, Victor E.A. Gerdes4 and M. T. Nurmohamed6, 1Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands, 3Rheumatology, VU University medical centre, Amsterdam, Netherlands, 4Internal Medicine, Slotervaart Hospital, Amsterdam, Netherlands, 5Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 6VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands

    Background/Purpose: There is accumulating evidence that rheumatoid arthritis (RA) should be considered as prothrombotic state, explaining the increased risk of thromboembolic events. Suppressing inflammation could…
  • Abstract Number: 376 • 2012 ACR/ARHP Annual Meeting

    Strategies for Use of Prednisolone in Rheumatoid Arthritis Have Changed Over the Past Decade: Data From the NOR-DMARD Register

    Anna-Birgitte Aga1, Elisabeth Lie2, Till Uhlig2, Tore K. Kvien2 and Espen A. Haavardsholm3, 1Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: Focus on early aggressive treatment in patients with rheumatoid arthritis (RA) has increased during the past decade. There is evidence for the efficacy of…
  • Abstract Number: 684 • 2012 ACR/ARHP Annual Meeting

    Correlation of Signal Transducers and Activators of Transcription-1 and Microrna-146a with Anaemia and Other Clinical Features in Systemic Lupus Erythematosus Patients

    Paul R. Dominguez-Gutierrez1, Angela Ceribelli1, Minoru Satoh2, Eric S. Sobel3, Yi Li2, Westley H. Reeves4 and Edward K.L. Chan1, 1Oral Biology, University of Florida, Gainesville, FL, 2Medicine, University of Florida, Gainesville, FL, 3Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, 4Rheumatology & Clinical Imm, University of Florida, Gainesville, FL

    Background/Purpose: Anaemia is one of the most common haematological manifestations in SLE patients, occurring in about 50% of active cases. STAT1 is a critical signalling…
  • Abstract Number: 1224 • 2012 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Disease Activity During Pregnancy Affects the Postnatal Catch-up Growth of the Child

    Florentien D.O. de Steenwinkel1, Anita C.S. Hokken-Koelega2, Maria A.J. de Ridder3, Johanna M.W. Hazes4 and Radboud J.E.M. Dolhain1, 1Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 2Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands, 3Bio Statistics, Erasmus Medical Center, Rotterdam, Netherlands, 4Rheumatology, Erasmus MC, Rotterdam, Netherlands

    Background/Purpose:  Active rheumatoid arthritis (RA) during pregnancy is associated with lower birth weight. Active RA during pregnancy can be treated with prednisone. However, studies have…
  • Abstract Number: 1274 • 2012 ACR/ARHP Annual Meeting

    Relationship Between Morning Stiffness Duration and Severity, Pain Intensity, and Measures of Disease Activity in a 12 Week Efficacy Study of a Modified (Delayed-Release) Prednisone Plus Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

    Frank Buttgereit1, John R. Kirwan2, Kenneth G. Saag3, Reike Alten4, Amy Grahn5, Patricia Rice6 and Maarten Boers7, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, 3Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, 4Charité Univ Medicine, Berlin, Germany, 5Clinical Development, Horizon Pharma, Inc, Deerfield, IL, 6Statistics, CliniRx Research, Naperville, IL, 7Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: RA patients typically present with pain and morning stiffness (MS).  MS is predictive of both functional disability and escalated RA care, but the best…
  • Abstract Number: 1696 • 2012 ACR/ARHP Annual Meeting

    Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone

    Tim Pottel1, Christoph Schäfer2 and Gernot Keyßer2, 1Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06114 Halle (Saale), Germany, 2Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06120 Halle (Saale), Germany

    Background/Purpose: The katabolic effects of a systemic treatment with glucocorticoids can lead to a progressive atrophy of the skin. Clinical observation suggests a more pronounced…
  • Abstract Number: 2120 • 2012 ACR/ARHP Annual Meeting

    Predictive Value of Anti-CCP Positivity On Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results From the Swedish EIRA Study

    Saedis Saevarsdottir1, Marie Holmqvist2, Johan Askling3, Lars Alfredsson4 and Lars Klareskog5, 1Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden, 4Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 5Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Does anti-CCP-positivity predict disease course and response to therapy in early rheumatoid arthritis (RA)? Methods: We retrieved clinical follow-up data for patients entering the…
  • Abstract Number: 2125 • 2012 ACR/ARHP Annual Meeting

    Response to Methotrexate Plus Prednisone in Camera II Using a Multi-Biomarker Disease Activity (VectraTM DA) Test and DAS28-ESR

    J.W.J. Bijlsma1, M. Verhoef-Jurgens2, M.F. Bakker1, J.W.G. Jacobs1, F.P.J.G. Lafeber1, P.M.J. Welsing3, G. Cavet4, D. Chernoff4 and D.J. Haney4, 1Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Rheumatology & Clinical Immunology, F02.127, University Medical Center Utrecht, Utrecht, Netherlands, 4Crescendo Bioscience, Inc., South San Francisco, CA

    Background/Purpose: The CAMERA II study (Computer Assisted Management in Early RA) demonstrated that the addition of prednisone to a MTX-based tight control strategy increased effectiveness…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology